Kestra Medical Technologies, Ltd. officer Traci S. Umberger filed a Form 144 notice on October 27, 2026, proposing the sale of 30,000 shares of common stock acquired through a broker-assisted cashless exercise of employee stock options.

Key Highlights

  • Proposed sale: Traci S. Umberger, an officer of Kestra Medical Technologies, Ltd., proposes to sell 30,000 shares of common stock with an aggregate market value of $900,880.51.
  • Acquisition method: The 30,000 shares were acquired on October 27, 2026, via a broker-assisted cashless exercise of employee stock options from Kestra Medical Technologies, Ltd.
  • Broker: The proposed sale is to be executed through Merrill Lynch, 225 Liberty Street, Floor 37, New York, NY 10281.
  • Shares outstanding: According to the filing, 59,561,795 shares of common stock were outstanding at the time of the notice.
  • Prior three-month sales: Umberger sold a total of 125,809 shares in five separate transactions between July 30, 2026, and October 21, 2026, generating combined gross proceeds of $3,317,181.04.
  • Trading plan: The filing indicates a Rule 10b5-1 plan adoption or instruction date of July 21, 2026.

Umberger Proposes October 2026 Stock Option Exercise and Sale at Kestra Medical

According to the Form 144 filed with the U.S. Securities and Exchange Commission, Traci S. Umberger, identified as an officer of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), filed notice of a proposed sale of 30,000 shares of common stock on October 27, 2026. The filing states the shares were acquired the same day through a broker-assisted cashless exercise of employee stock options granted by the company, with payment made on October 27, 2026. The aggregate market value of the proposed sale is listed as $900,880.51.

The filing also discloses five sales of common stock by Umberger during the three months preceding the notice. Those transactions, listed in the filing, occurred on July 30, 2026 (5,887 shares, $133,892.22 gross proceeds), July 31, 2026 (8,752 shares, $197,837.19), August 3, 2026 (7,590 shares, $181,061.84), August 4, 2026 (3,580 shares, $86,073.05), and October 21, 2026 (100,000 shares, $2,718,316.74). The combined gross proceeds from those five transactions total $3,317,181.04 as reported in the filing.

The notice identifies a Rule 10b5-1 plan adoption or instruction date of July 21, 2026. By signing the form, Umberger represented, as required by the form, that she "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." The filing does not indicate the per-share exercise price of the options.

What Was Disclosed

Kestra Medical Technologies officer Traci S. Umberger filed a Form 144 on October 27, 2026, to propose the sale of 30,000 shares worth $900,880.51, acquired via a cashless stock option exercise, through Merrill Lynch on NASDAQ.